VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 1034 · 116th Congress

Phair Pricing Act of 2019

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

DCR CollinsSponsor
77 cosponsors · 18 D, 59 R
TBR Budd RCR Crawford BCR Carter HGR Griffith VGD Gonzalez WHR Hurd PRR Roe ASR Scott RWR Wittman BWR Westerman TGR Graves RMR Marshall LGR Gohmert BBR Byrne MRR Roby FVD Vela BLR Loudermilk MRR Rogers GGR Graves LGR Gooden JHR Hice CHR Higgins JJR Joyce SKR King MMR Meadows CRD Ruppersberger DLD Loebsack PWD Welch JGD Golden RAR Allen RAR Abraham KAR Armstrong CCR Collins BCR Cline SDR Duffy CFR Fleischmann MGR Guest AHR Harris JHR Herrera Beutler HJD Johnson CMR McMorris Rodgers DRR Rouzer CSR Stewart SWR Womack KRD Rice HCD Cuellar AFD Finkenauer SDD Davids BPR Posey DMR McKinley LBD Blunt Rochester ABD Brindisi JHR Hill JRR Rutherford MGR Gallagher FKR Keller RNR Norman BGR Gibbs PKR King CAD Axne MBR Brooks BLR Long TCR Cole JCR Comer DKR Kustoff VHR Hartzler JVD Van Drew KHD Horn WSR Steube ZLD Lofgren GTR Thompson MJR Johnson MCD Cartwright TKR Kelly RSR Spano TBR Burchett JRR Rose

10 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale.

What it does: CRS summary · Introduced in House · Feb 7, 2019

Phair Pricing Act of 2019

This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale.

Specifically, negotiated prices offered under a prescription drug plan (PDP) must be disclosed at the point-of-sale; the disclosed price must include specified adjustments, payments, and fees that are negotiated with the pharmacy (e.g., dispensing fees) by the PDP sponsor or pharmacy benefit manager.

Additionally, the Centers for Medicare & Medicaid Services must establish certain quality measures for PDP sponsors to use when determining incentive payments and adjustments (e.g., performance payments) to pharmacies.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Phair Pricing Act of 2019

Latest action (Feb 7, 2019): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Feb 7, 2019

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.